Tirzepatide once weekly for the treatment of obesity
Up to ~20.9% mean weight reduction at highest studied dose.
View sourceBack to catalog
Weight LossTrendingHigh evidence
Tirzepatide
Dual GIP/GLP-1 agonist showing superior average weight-loss efficacy versus semaglutide in head-to-head and parallel trial programs.
Mechanism
Activates both GIP and GLP-1 receptors, amplifying satiety signaling and improving glycemic control beyond single-pathway GLP-1 agonism.
- Weight management
- Type 2 diabetes
Dosing ranges
Educational ranges only — not medical advice. Confirm protocols with a qualified clinician.
| Use case | Typical range | Frequency | Notes |
|---|---|---|---|
| Weight management | 2.5 → 15 mg | Weekly | Step-up every 4 weeks based on response/tolerability |
Clinical evidence
High evidenceCautions
- Higher rates of nausea at upper doses
- Same boxed-warning class considerations as GLP-1 RAs
- Requires medical titration and monitoring
Provider comparison
Affiliate-style comparison cards for clinics, telehealth, and research suppliers. Verify licensing and product quality before purchasing.
Fountain Health
telehealth
From $249/mo
Licensed clinician consult + ongoing titration support
Compare offerPeakRx Clinic
clinic
From $189/mo
In-person labs available in select metros
Compare offerResearch Supply Co.
research
Vial pricing
Research-only sourcing — not for human consumption labeling
View listing